Please use this identifier to cite or link to this item:
Title: Erythropoiesis-stimulating Agents in Critically Ill Trauma Patients: A Systematic Review and Meta-analysis.
Austin Authors: French, Craig J;Glassford, Neil J;Gantner, Dashiell;Higgins, Alisa M;Cooper, David James;Nichol, Alistair;Skrifvars, Markus B;Imberger, Georgina;Presneill, Jeffrey;Bailey, Michael;Bellomo, Rinaldo 
Affiliation: Division of Intensive Care, Department of Anesthesiology, Intensive Care and Pain Medicine, Helsinki University Hospital and Helsinki University, Helsinki, Finland
Royal Brisbane and Women's Hospital, Brisbane, Australia
The University of Melbourne, Parkville, Melbourne, Australia
Departments of Anaesthesia and Intensive Care, Western Health, Gordon Street, Footscray, Melbourne, Australia
Department of Intensive Care, Austin Health, Heidelberg, Victoria, Australia
Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
Department of Intensive Care, The Alfred, Melbourne, Australia
St Vincent's University Hospital, Dublin, Ireland
Issue Date: Jan-2017
Publication information: Annals of surgery 2017; 265(1): 54-62
Abstract: To perform a meta-analysis of all relevant randomized controlled trials assessing the effect of erythropoiesis-stimulating agents (ESAs) in critically ill trauma patients. ESAs have effects beyond erythropoiesis. The administration of the ESA epoetin alfa to critically ill trauma patients has been associated with a reduction in mortality. We performed a systematic review and meta-analysis with trial sequential analysis. We searched Medline, Medline in Process, and other nonindexed citations, EMBASE, and the Cochrane Database from inception until September 9, 2015, for randomized controlled trials comparing ESAs to placebo (or no ESA). We identified 9 eligible studies that randomly assigned 2607 critically ill patients after trauma to an ESA or placebo (or no ESA). Compared with placebo (or no ESA), ESA therapy was associated with a substantial reduction in mortality [risk ratio (RR) 0.63, 95% confidence interval (CI) 0.49-0.79, P = 0.0001, I = 0%). In patients with traumatic brain injury, ESA therapy did not increase the number of patients surviving with moderate disability or good recovery (RR 1.00, 95% CI 0.88-1.15, P = 0.95, I = 0%). With the dosing regimens employed in the included studies, ESA therapy did not increase the risk of lower limb proximal deep venous thrombosis (RR 0.97, 95% CI 0.72-1.29, P = 0.78, I = 0%). The administration of ESAs to critically ill trauma patients is associated with a significant improvement in mortality without an increase in the rate of lower limb proximal deep venous thrombosis. Given the worldwide public health significance of these findings research to validate or refute them is required.
DOI: 10.1097/SLA.0000000000001746
ORCID: 0000-0002-1650-8939
PubMed URL: 27070933
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 2, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.